pdf   xlsx method abbreviations

lung cancer : non small cell (NSCLC), gene alteration target therapy , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.76 [0.60, 0.95]< 17%5 studies (5/-)99.1 %some concernnot evaluable moderatecrucial-
progression or deaths (PFS) 0.36 [0.24, 0.52]< 170%4 studies (4/-)100.0 %some concernnot evaluable moderateimportant-
RFS/DFS 0.20 [0.14, 0.29]< 10%1 study (1/-)100.0 %NAnot evaluable important-
DCR 3.52 [2.20, 5.64]> 10%2 studies (2/-)100.0 %some concernnot evaluable moderatenon important-
events or deaths (EFS) 0.17 [0.11, 0.26]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
objective responses (ORR) 2.99 [0.88, 10.17]> 193%4 studies (4/-)96.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE (any grade) 1.52 [0.40, 5.73]< 166%4 studies (4/-)27.0 %some concernnot evaluable moderatenon important-
AE (grade 3-4) 0.70 [0.27, 1.83]< 186%3 studies (3/-)76.4 %some concernnot evaluable moderatenon important-
AE leading to death (grade 5) 0.71 [0.30, 1.70]< 10%4 studies (4/-)77.9 %lownot evaluable highnon important-
AE leading to treatment discontinuation (any grade) 1.67 [0.30, 9.31]< 194%2 studies (2/-)27.9 %lownot evaluable highnon important-
SAE (any grade) 0.84 [0.57, 1.23]< 10%2 studies (2/-)81.1 %lownot evaluable highnon important-
TRAE (any grade) 0.56 [0.32, 1.00]< 152%3 studies (3/-)97.4 %lownot evaluable highnon important-
TRAE (grade 3-4) 0.69 [0.01, 36.44]< 185%2 studies (2/-)57.1 %some concernnot evaluable moderatenon important-
TRAE leading to death (grade 5) 0.99 [0.02, 50.39]< 10%1 study (1/-)50.3 %NAnot evaluable non important-

AE (grade 3-4) endpoints 00

Cough AE (grade 3-4) 0.85 [0.05, 13.87]< 10%2 studies (2/-)54.6 %some concernnot evaluable moderatenon important-
Decreased appetite AE (grade 3-4) 4.09 [0.18, 91.02]< 10%1 study (1/-)19.0 %NAnot evaluable non important-
Dermatitis acneiform AE (grade 3-4) 1.02 [0.02, 51.45]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
Diarrhoea AE (grade 3-4) 5.23 [0.87, 31.26]< 10%2 studies (2/-)3.5 %some concernnot evaluable moderatenon important-
Dry skin AE (grade 3-4) 1.30 [0.10, 17.27]< 10%2 studies (2/-)42.2 %some concernnot evaluable moderatenon important-
Pruritus AE (grade 3-4) 0.85 [0.05, 13.87]< 10%2 studies (2/-)54.6 %some concernnot evaluable moderatenon important-
Stomatitis AE (grade 3-4) 4.14 [0.27, 64.28]< 124%2 studies (2/-)15.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons